Literature DB >> 34282403

Comment on: Impact of switching from ranibizumab to aflibercept on the number of intravitreous injection and follow up visit in wet AMD: results of real-life ELU study.

Dan Călugăru1, Mihai Călugăru1.   

Abstract

Entities:  

Year:  2021        PMID： 34282403      PMCID： PMC8243194          DOI： 10.18240/ijo.2021.07.26

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN： 2222-3959            Impact factor:   1.779


× No keyword cloud information.
  8 in total

1.  Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes.

Authors:  Sylvie Julien; Antje Biesemeier; Tatjana Taubitz; Ulrich Schraermeyer
Journal:  Br J Ophthalmol       Date:  2014-01-23       Impact factor: 4.638

Review 2.  TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations.

Authors:  K Bailey Freund; Jean-François Korobelnik; Robert Devenyi; Carsten Framme; John Galic; Edward Herbert; Hans Hoerauf; Paolo Lanzetta; Stephan Michels; Paul Mitchell; Jordi Monés; Carl Regillo; Ramin Tadayoni; James Talks; Sebastian Wolf
Journal:  Retina       Date:  2015-08       Impact factor: 4.256

3.  High-frequency aflibercept injections in persistent neovascular age-related macular degeneration.

Authors:  Ilkay Kilic Muftuoglu; William R Freeman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-08-05       Impact factor: 3.117

4.  Long-Term Results of Pro Re Nata Regimen of Aflibercept Treatment in Persistent Neovascular Age-Related Macular Degeneration.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Am J Ophthalmol       Date:  2016-11-11       Impact factor: 5.258

Review 5.  Bruch's membrane pathology: A mechanistic perspective.

Authors:  Aishwarya Murali; Subramanian Krishnakumar; Anuradha Subramanian; Sowmya Parameswaran
Journal:  Eur J Ophthalmol       Date:  2020-04-28       Impact factor: 2.597

6.  Impact of switching from ranibizumab to aflibercept on the number of intravitreous injection and follow up visit in wet AMD: results of real life ELU study.

Authors:  Frederic Queguiner; Kristina Bezirganyan; Jean Christophe Courjaret; Laurence Curel; Guillaume Penaranda; Maud Righini Chossegros
Journal:  Int J Ophthalmol       Date:  2020-02-18       Impact factor: 1.779

7.  Choroidal Thickness Changes After Intravitreal Antivascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration: Ranibizumab Versus Aflibercept.

Authors:  Magda Gharbiya; Filippo Cruciani; Cesare Mariotti; Francesca Grandinetti; Marco Marenco; Vittorio Cacace
Journal:  J Ocul Pharmacol Ther       Date:  2015-06-03       Impact factor: 2.671

8.  Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group.

Authors:  Richard F Spaide; Glenn J Jaffe; David Sarraf; K Bailey Freund; Srinivas R Sadda; Giovanni Staurenghi; Nadia K Waheed; Usha Chakravarthy; Philip J Rosenfeld; Frank G Holz; Eric H Souied; Salomon Y Cohen; Giuseppe Querques; Kyoko Ohno-Matsui; David Boyer; Alain Gaudric; Barbara Blodi; Caroline R Baumal; Xiaoxin Li; Gabriel J Coscas; Alexander Brucker; Lawrence Singerman; Phil Luthert; Steffen Schmitz-Valckenberg; Ursula Schmidt-Erfurth; Hans E Grossniklaus; David J Wilson; Robyn Guymer; Lawrence A Yannuzzi; Emily Y Chew; Karl Csaky; Jordi M Monés; Daniel Pauleikhoff; Ramin Tadayoni; James Fujimoto
Journal:  Ophthalmology       Date:  2019-11-14       Impact factor: 12.079
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.